Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 27 entries
Sorted by: Best Match Show Resources per page
Contemporary Management of Localized Resectable Pancreatic Cancer.

Cancers

Kommalapati A, Tella SH, Goyal G, Ma WW, Mahipal A.
PMID: 29361690
Cancers (Basel). 2018 Jan 20;10(1). doi: 10.3390/cancers10010024.

Pancreatic cancer is the third most common cause of cancer deaths in the United States. Surgical resection with negative margins still constitutes the cornerstone of potentially curative therapy, but is possible only in 15-20% of patients at the time...

Cite
Kommalapati A, Tella SH, Goyal G, et al. Contemporary Management of Localized Resectable Pancreatic Cancer. Cancers (Basel). 2018;10(1)doi: 10.3390/cancers10010024.
Kommalapati, A., Tella, S. H., Goyal, G., Ma, W. W., & Mahipal, A. (2018). Contemporary Management of Localized Resectable Pancreatic Cancer. Cancers, 10(1), . https://doi.org/10.3390/cancers10010024
Kommalapati, Anuhya, et al. "Contemporary Management of Localized Resectable Pancreatic Cancer." Cancers vol. 10,1 (2018). doi: https://doi.org/10.3390/cancers10010024
Kommalapati A, Tella SH, Goyal G, Ma WW, Mahipal A. Contemporary Management of Localized Resectable Pancreatic Cancer. Cancers (Basel). 2018 Jan 20;10(1). doi: 10.3390/cancers10010024. PMID: 29361690; PMCID: PMC5789374.
Copy Download .nbib Format: NLM
Profile of Abaloparatide and Its Potential in the Treatment of Postmenopausal Osteoporosis.

Cureus

Tella SH, Kommalapati A, Correa R.
PMID: 28680788
Cureus. 2017 May 31;9(5):e1300. doi: 10.7759/cureus.1300.

Abaloparatide (previously known as BA058) is a synthetic 34-amino acid peptide and novel selective activator of parathyroid hormone receptor 1 (PTHR1) currently under development as a new anabolic agent in the management of osteoporosis. This paper reviews the profile...

Cite
Tella SH, Kommalapati A, Correa R. Profile of Abaloparatide and Its Potential in the Treatment of Postmenopausal Osteoporosis. Cureus. 2017;9(5):e1300doi: 10.7759/cureus.1300.
Tella, S. H., Kommalapati, A., & Correa, R. (2017). Profile of Abaloparatide and Its Potential in the Treatment of Postmenopausal Osteoporosis. Cureus, 9(5), e1300. https://doi.org/10.7759/cureus.1300
Tella, Sri Harsha, et al. "Profile of Abaloparatide and Its Potential in the Treatment of Postmenopausal Osteoporosis." Cureus vol. 9,5 (2017): e1300. doi: https://doi.org/10.7759/cureus.1300
Tella SH, Kommalapati A, Correa R. Profile of Abaloparatide and Its Potential in the Treatment of Postmenopausal Osteoporosis. Cureus. 2017 May 31;9(5):e1300. doi: 10.7759/cureus.1300. PMID: 28680788; PMCID: PMC5493470.
Copy Download .nbib Format: NLM
Clinicopathological features and outcomes of fibrolamellar hepatocellular carcinoma.

Journal of gastrointestinal oncology

Chakrabarti S, Tella SH, Kommalapati A, Huffman BM, Yadav S, Riaz IB, Goyal G, Mody K, Borad M, Cleary S, Smoot RL, Mahipal A.
PMID: 31183207
J Gastrointest Oncol. 2019 Jun;10(3):554-561. doi: 10.21037/jgo.2019.01.35.

BACKGROUND: Clinicopathological features and the outcomes of patients with fibrolamellar hepatocellular carcinoma (FLHCC) are not clearly defined.METHODS: Data were collected by retrospective chart review on 42 patients with FLHCC treated between 1990 and 2017 at Mayo Clinic.RESULTS: Of 42...

Cite
Chakrabarti S, Tella SH, Kommalapati A, et al. Clinicopathological features and outcomes of fibrolamellar hepatocellular carcinoma. J Gastrointest Oncol. 2019;10(3):554-561doi: 10.21037/jgo.2019.01.35.
Chakrabarti, S., Tella, S. H., Kommalapati, A., Huffman, B. M., Yadav, S., Riaz, I. B., Goyal, G., Mody, K., Borad, M., Cleary, S., Smoot, R. L., & Mahipal, A. (2019). Clinicopathological features and outcomes of fibrolamellar hepatocellular carcinoma. Journal of gastrointestinal oncology, 10(3), 554-561. https://doi.org/10.21037/jgo.2019.01.35
Chakrabarti, Sakti, et al. "Clinicopathological features and outcomes of fibrolamellar hepatocellular carcinoma." Journal of gastrointestinal oncology vol. 10,3 (2019): 554-561. doi: https://doi.org/10.21037/jgo.2019.01.35
Chakrabarti S, Tella SH, Kommalapati A, Huffman BM, Yadav S, Riaz IB, Goyal G, Mody K, Borad M, Cleary S, Smoot RL, Mahipal A. Clinicopathological features and outcomes of fibrolamellar hepatocellular carcinoma. J Gastrointest Oncol. 2019 Jun;10(3):554-561. doi: 10.21037/jgo.2019.01.35. PMID: 31183207; PMCID: PMC6534717.
Copy Download .nbib Format: NLM
Alliance A011801 (compassHER2 RD): postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancer.

Future oncology (London, England)

O'Sullivan CC, Ballman KV, McCall L, Kommalapati A, Zemla T, Weiss A, Mitchell M, Blinder V, Tung NM, Irvin WJ, Lee M, Goetz MP, Symmans WF, Borges VF, Krop I, Carey LA, Partridge AH.
PMID: 34636255
Future Oncol. 2021 Dec;17(34):4665-4676. doi: 10.2217/fon-2021-0753. Epub 2021 Oct 12.

This report describes the rationale, purpose and design of A011801 (CompassHER2 RD), an ongoing prospective, multicenter, Phase III randomized trial. Eligible patients in the United States (US) and Canada with high-risk (defined as ER-negative and/or node-positive) HER2-positive (HER2+) residual...

Cite
O'Sullivan CC, Ballman KV, McCall L, et al. Alliance A011801 (compassHER2 RD): postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancer. Future Oncol. 2021;17(34):4665-4676doi: 10.2217/fon-2021-0753.
O'Sullivan, C. C., Ballman, K. V., McCall, L., Kommalapati, A., Zemla, T., Weiss, A., Mitchell, M., Blinder, V., Tung, N. M., Irvin, W. J., Lee, M., Goetz, M. P., Symmans, W. F., Borges, V. F., Krop, I., Carey, L. A., & Partridge, A. H. (2021). Alliance A011801 (compassHER2 RD): postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancer. Future oncology (London, England), 17(34), 4665-4676. https://doi.org/10.2217/fon-2021-0753
O'Sullivan, Ciara C, et al. "Alliance A011801 (compassHER2 RD): postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancer." Future oncology (London, England) vol. 17,34 (2021): 4665-4676. doi: https://doi.org/10.2217/fon-2021-0753
O'Sullivan CC, Ballman KV, McCall L, Kommalapati A, Zemla T, Weiss A, Mitchell M, Blinder V, Tung NM, Irvin WJ, Lee M, Goetz MP, Symmans WF, Borges VF, Krop I, Carey LA, Partridge AH. Alliance A011801 (compassHER2 RD): postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancer. Future Oncol. 2021 Dec;17(34):4665-4676. doi: 10.2217/fon-2021-0753. Epub 2021 Oct 12. PMID: 34636255; PMCID: PMC8600597.
Copy Download .nbib Format: NLM
Aspirin and Statin Use and the Risk of Gallbladder Cancer.

Cancers

Prasai K, Tella SH, Yadav S, Kommalapati A, Mara K, Mady M, Hassan MA, Wongjarupong N, Rodriguez-Payan N, Borad M, Patel T, Roberts LR, Mahipal A.
PMID: 33803387
Cancers (Basel). 2021 Mar 09;13(5). doi: 10.3390/cancers13051186.

Aspirin and statin drugs have been associated with reduced risk of several gastrointestinal cancers, but their association with gallbladder cancer (GBC) has not been well established. We evaluated the association of aspirin and statins with the risk of GBC....

Cite
Prasai K, Tella SH, Yadav S, et al. Aspirin and Statin Use and the Risk of Gallbladder Cancer. Cancers (Basel). 2021;13(5)doi: 10.3390/cancers13051186.
Prasai, K., Tella, S. H., Yadav, S., Kommalapati, A., Mara, K., Mady, M., Hassan, M. A., Wongjarupong, N., Rodriguez-Payan, N., Borad, M., Patel, T., Roberts, L. R., & Mahipal, A. (2021). Aspirin and Statin Use and the Risk of Gallbladder Cancer. Cancers, 13(5), . https://doi.org/10.3390/cancers13051186
Prasai, Kritika, et al. "Aspirin and Statin Use and the Risk of Gallbladder Cancer." Cancers vol. 13,5 (2021). doi: https://doi.org/10.3390/cancers13051186
Prasai K, Tella SH, Yadav S, Kommalapati A, Mara K, Mady M, Hassan MA, Wongjarupong N, Rodriguez-Payan N, Borad M, Patel T, Roberts LR, Mahipal A. Aspirin and Statin Use and the Risk of Gallbladder Cancer. Cancers (Basel). 2021 Mar 09;13(5). doi: 10.3390/cancers13051186. PMID: 33803387; PMCID: PMC7967123.
Copy Download .nbib Format: NLM
9-Ethynyl noscapine induces G2/M arrest and apoptosis by disrupting tubulin polymerization in cervical cancer.

Drug development research

Nagireddy PKR, Kumar D, Kommalapati VK, Pedapati RK, Kojja V, Tangutur AD, Kantevari S.
PMID: 34612529
Drug Dev Res. 2021 Oct 06; doi: 10.1002/ddr.21888. Epub 2021 Oct 06.

Noscapine is a phthalide isoquinoline alkaloid present in the latex of Papaver somniferum and has demonstrated potent antitumor activity in various cancer models. Structural changes in the core molecule of noscapine architecture have produced a number of potent analogs....

Cite
Nagireddy PKR, Kumar D, Kommalapati VK, et al. 9-Ethynyl noscapine induces G2/M arrest and apoptosis by disrupting tubulin polymerization in cervical cancer. Drug Dev Res. 2021;doi: 10.1002/ddr.21888.
Nagireddy, P. K. R., Kumar, D., Kommalapati, V. K., Pedapati, R. K., Kojja, V., Tangutur, A. D., & Kantevari, S. (2021). 9-Ethynyl noscapine induces G2/M arrest and apoptosis by disrupting tubulin polymerization in cervical cancer. Drug development research, . https://doi.org/10.1002/ddr.21888
Nagireddy, Praveen Kumar Reddy, et al. "9-Ethynyl noscapine induces G2/M arrest and apoptosis by disrupting tubulin polymerization in cervical cancer." Drug development research vol. (2021). doi: https://doi.org/10.1002/ddr.21888
Nagireddy PKR, Kumar D, Kommalapati VK, Pedapati RK, Kojja V, Tangutur AD, Kantevari S. 9-Ethynyl noscapine induces G2/M arrest and apoptosis by disrupting tubulin polymerization in cervical cancer. Drug Dev Res. 2021 Oct 06; doi: 10.1002/ddr.21888. Epub 2021 Oct 06. PMID: 34612529.
Copy Download .nbib Format: NLM
Age estimation by assessment of dentin translucency in single rooted permanent teeth.

Journal of international oral health : JIOH

Kattappagari KK, Kommalapati RK, Katuri D, Murakonda RS, Chitturi RT, Reddy BV.
PMID: 25628481
J Int Oral Health. 2014 Nov-Dec;6(6):37-40.

BACKGROUND: To estimate the age by evaluating the area and length of dentin translucency in single-rooted ground sections of extracted teeth using digital Vernier caliper and stereomicroscope.MATERIALS AND METHODS: Ground sections of single rooted permanent anterior teeth were made...

Cite
Kattappagari KK, Kommalapati RK, Katuri D, et al. Age estimation by assessment of dentin translucency in single rooted permanent teeth. J Int Oral Health. 2014;6(6):37-40
Kattappagari, K. K., Kommalapati, R. K., Katuri, D., Murakonda, R. S., Chitturi, R. T., & Reddy, B. V. (2014). Age estimation by assessment of dentin translucency in single rooted permanent teeth. Journal of international oral health : JIOH, 6(6), 37-40.
Kattappagari, Kiran Kumar, et al. "Age estimation by assessment of dentin translucency in single rooted permanent teeth." Journal of international oral health : JIOH vol. 6,6 (2014): 37-40.
Kattappagari KK, Kommalapati RK, Katuri D, Murakonda RS, Chitturi RT, Reddy BV. Age estimation by assessment of dentin translucency in single rooted permanent teeth. J Int Oral Health. 2014 Nov-Dec;6(6):37-40. PMID: 25628481; PMCID: PMC4295452.
Copy Download .nbib Format: NLM
Cost-effectiveness in managing skeletal related events in breast cancer: a strategy of less-intense dosing schedule of bone modifying agents.

Translational cancer research

Tella SH, Kommalapati A, Singhi RK.
PMID: 29863174
Transl Cancer Res. 2018 Feb;7:S81-S84. doi: 10.21037/tcr.2018.01.07.

No abstract available.

Cite
Tella SH, Kommalapati A, Singhi RK. Cost-effectiveness in managing skeletal related events in breast cancer: a strategy of less-intense dosing schedule of bone modifying agents. Transl Cancer Res. 2018;7:S81-S84doi: 10.21037/tcr.2018.01.07.
Tella, S. H., Kommalapati, A., & Singhi, R. K. (2018). Cost-effectiveness in managing skeletal related events in breast cancer: a strategy of less-intense dosing schedule of bone modifying agents. Translational cancer research, 7S81-S84. https://doi.org/10.21037/tcr.2018.01.07
Tella, Sri Harsha, et al. "Cost-effectiveness in managing skeletal related events in breast cancer: a strategy of less-intense dosing schedule of bone modifying agents." Translational cancer research vol. 7 (2018): S81-S84. doi: https://doi.org/10.21037/tcr.2018.01.07
Tella SH, Kommalapati A, Singhi RK. Cost-effectiveness in managing skeletal related events in breast cancer: a strategy of less-intense dosing schedule of bone modifying agents. Transl Cancer Res. 2018 Feb;7:S81-S84. doi: 10.21037/tcr.2018.01.07. PMID: 29863174; PMCID: PMC5983387.
Copy Download .nbib Format: NLM
Alliance A011801 (compassHER2 RD): postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancer.

Future oncology (London, England)

O'Sullivan CC, Ballman KV, McCall L, Kommalapati A, Zemla T, Weiss A, Mitchell M, Blinder V, Tung NM, Irvin WJ, Lee M, Goetz MP, Symmans WF, Borges VF, Krop I, Carey LA, Partridge AH.
PMID: 34636255
Future Oncol. 2021 Dec;17(34):4665-4676. doi: 10.2217/fon-2021-0753. Epub 2021 Oct 12.

This report describes the rationale, purpose and design of A011801 (CompassHER2 RD), an ongoing prospective, multicenter, Phase III randomized trial. Eligible patients in the United States (US) and Canada with high-risk (defined as ER-negative and/or node-positive) HER2-positive (HER2+) residual...

Cite
O'Sullivan CC, Ballman KV, McCall L, et al. Alliance A011801 (compassHER2 RD): postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancer. Future Oncol. 2021;17(34):4665-4676doi: 10.2217/fon-2021-0753.
O'Sullivan, C. C., Ballman, K. V., McCall, L., Kommalapati, A., Zemla, T., Weiss, A., Mitchell, M., Blinder, V., Tung, N. M., Irvin, W. J., Lee, M., Goetz, M. P., Symmans, W. F., Borges, V. F., Krop, I., Carey, L. A., & Partridge, A. H. (2021). Alliance A011801 (compassHER2 RD): postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancer. Future oncology (London, England), 17(34), 4665-4676. https://doi.org/10.2217/fon-2021-0753
O'Sullivan, Ciara C, et al. "Alliance A011801 (compassHER2 RD): postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancer." Future oncology (London, England) vol. 17,34 (2021): 4665-4676. doi: https://doi.org/10.2217/fon-2021-0753
O'Sullivan CC, Ballman KV, McCall L, Kommalapati A, Zemla T, Weiss A, Mitchell M, Blinder V, Tung NM, Irvin WJ, Lee M, Goetz MP, Symmans WF, Borges VF, Krop I, Carey LA, Partridge AH. Alliance A011801 (compassHER2 RD): postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancer. Future Oncol. 2021 Dec;17(34):4665-4676. doi: 10.2217/fon-2021-0753. Epub 2021 Oct 12. PMID: 34636255; PMCID: PMC8600597.
Copy Download .nbib Format: NLM
Imidazo[2,1-.

ACS omega

Nagireddy PKR, Kommalapati VK, Siva Krishna V, Sriram D, Tangutur AD, Kantevari S.
PMID: 31763563
ACS Omega. 2019 Nov 05;4(21):19382-19398. doi: 10.1021/acsomega.9b02789. eCollection 2019 Nov 19.

Noscapine, a phthalide isoquinoline alkaloid isolated from the opium poppy

Cite
Nagireddy PKR, Kommalapati VK, Siva Krishna V, et al. Imidazo[2,1-. ACS Omega. 2019;4(21):19382-19398doi: 10.1021/acsomega.9b02789.
Nagireddy, P. K. R., Kommalapati, V. K., Siva Krishna, V., Sriram, D., Tangutur, A. D., & Kantevari, S. (2019). Imidazo[2,1-. ACS omega, 4(21), 19382-19398. https://doi.org/10.1021/acsomega.9b02789
Nagireddy, Praveen Kumar Reddy, et al. "Imidazo[2,1-." ACS omega vol. 4,21 (2019): 19382-19398. doi: https://doi.org/10.1021/acsomega.9b02789
Nagireddy PKR, Kommalapati VK, Siva Krishna V, Sriram D, Tangutur AD, Kantevari S. Imidazo[2,1-. ACS Omega. 2019 Nov 05;4(21):19382-19398. doi: 10.1021/acsomega.9b02789. eCollection 2019 Nov 19. PMID: 31763563; PMCID: PMC6868913.
Copy Download .nbib Format: NLM
Quisinostat mediated autophagy is associated with differentiation in neuroblastoma SK-N-SH cells.

Molecular biology reports

Kommalapati VK, Kumar D, Tangutur AD.
PMID: 34125328
Mol Biol Rep. 2021 May;48(5):4973-4979. doi: 10.1007/s11033-021-06481-z. Epub 2021 Jun 14.

Neuroblastoma (NB) is the most common childhood cancer that arises from the sympathetic nervous system. NB is characterized by poor prognosis. One of the strategies to control NB is activating the differentiation process in undifferentiated NB cells. Many differentiating...

Cite
Kommalapati VK, Kumar D, Tangutur AD. Quisinostat mediated autophagy is associated with differentiation in neuroblastoma SK-N-SH cells. Mol Biol Rep. 2021;48(5):4973-4979doi: 10.1007/s11033-021-06481-z.
Kommalapati, V. K., Kumar, D., & Tangutur, A. D. (2021). Quisinostat mediated autophagy is associated with differentiation in neuroblastoma SK-N-SH cells. Molecular biology reports, 48(5), 4973-4979. https://doi.org/10.1007/s11033-021-06481-z
Kommalapati, Vamsi Krishna, et al. "Quisinostat mediated autophagy is associated with differentiation in neuroblastoma SK-N-SH cells." Molecular biology reports vol. 48,5 (2021): 4973-4979. doi: https://doi.org/10.1007/s11033-021-06481-z
Kommalapati VK, Kumar D, Tangutur AD. Quisinostat mediated autophagy is associated with differentiation in neuroblastoma SK-N-SH cells. Mol Biol Rep. 2021 May;48(5):4973-4979. doi: 10.1007/s11033-021-06481-z. Epub 2021 Jun 14. PMID: 34125328.
Copy Download .nbib Format: NLM
Immune Check Point Inhibitors in Cancer Therapy: Beware of "Friendly Fire" Effect.

Research & reviews. Journal of hospital and clinical pharmacy

Kommalapati A, Sikder S, Tella SH.
PMID: 29291253
Res Rev J Hosp Clin Pharm. 2017 Jul;3(2):5-6. Epub 2017 Jun 08.

No abstract available.

Cite
Kommalapati A, Sikder S, Tella SH. Immune Check Point Inhibitors in Cancer Therapy: Beware of "Friendly Fire" Effect. Res Rev J Hosp Clin Pharm. 2017;3(2):5-6
Kommalapati, A., Sikder, S., & Tella, S. H. (2017). Immune Check Point Inhibitors in Cancer Therapy: Beware of "Friendly Fire" Effect. Research & reviews. Journal of hospital and clinical pharmacy, 3(2), 5-6.
Kommalapati, Anuhya, et al. "Immune Check Point Inhibitors in Cancer Therapy: Beware of "Friendly Fire" Effect." Research & reviews. Journal of hospital and clinical pharmacy vol. 3,2 (2017): 5-6.
Kommalapati A, Sikder S, Tella SH. Immune Check Point Inhibitors in Cancer Therapy: Beware of "Friendly Fire" Effect. Res Rev J Hosp Clin Pharm. 2017 Jul;3(2):5-6. Epub 2017 Jun 08. PMID: 29291253; PMCID: PMC5744671.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 27 entries